Cargando…

Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma

Objective. To analyze clinico-pathological features of Chinese patients with UPSC, and investigate roles of Her-2/neu protein expression and gene amplification in UPSC prognosis. Methods. Thirty-six patients with UPSC treated in Cancer Hospital of Fudan University from 1996 to 2006 were analysed ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Yulan, Wang, Huaying, Zhou, Xiaoyan, Yang, Wentao, Huang, Xiaowei, Lu, Yongming, Shi, Daren
Formato:	Texto
Lenguaje:	English
Publicado:	International Scholarly Research Network 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102014/ https://www.ncbi.nlm.nih.gov/pubmed/21647234 http://dx.doi.org/10.5402/2011/575327

Ejemplares similares

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients
por: Kattan, Joseph, et al.
Publicado: (2022)

Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases
por: Wang, Yao, et al.
Publicado: (2018)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
por: Li, Qingguo, et al.
Publicado: (2011)

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
por: Santin, A D, et al.
Publicado: (2004)

Which is worse: uterine papillary serous carcinomas or carcinosarcomas?
por: Song, Taejong, et al.
Publicado: (2011)

Papillary Serous Carcinoma of the Uterine Cervix with Lung Metastasis
por: Khan, Maliha, et al.
Publicado: (2014)

Adrenal Metastasis from Uterine Papillary Serous Carcinoma
por: Lubana, Sandeep Singh, et al.
Publicado: (2016)

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients
por: Dehghani, Mehdi, et al.
Publicado: (2020)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

Metastatic papillary serous uterine cancer presenting as a rash
por: Chang, Eric S., et al.
Publicado: (2016)

Evaluation of adjuvant therapy in women with uterine papillary serous cancer
por: Al Husaini, Hamed, et al.
Publicado: (2012)

Evaluation of HER2/neu Expression in High-Grade Endometrial Carcinoma and Its Clinicopathological Correlation
por: Sarmadi, Soheila, et al.
Publicado: (2019)

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
por: Santin, A D, et al.
Publicado: (2005)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Management of Women with Surgically Staged 1 Uterine Papillary Serous Cancer
por: Elit, Laurie, et al.
Publicado: (2011)

Cytologic Findings of Cervicovaginal Smears in Women with Uterine Papillary Serous Carcinoma
por: Park, Ji-Young, et al.
Publicado: (2005)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Serous carcinoma of the uterine cervix: Clinicopathological features differing from serous carcinomas of other female organs
por: Kitade, Shoko, et al.
Publicado: (2019)

Excellent Response to Palliative Chemotherapy for Pleural Recurrence of Uterine Papillary Serous Carcinoma
por: Singh, Shantanu, et al.
Publicado: (2013)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women
por: Singhai, Rajeev, et al.
Publicado: (2011)

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
por: Cocco, E, et al.
Publicado: (2009)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Rare brain metastasis with unusual characteristics in a late recurrence of stage IIIA uterine papillary serous carcinoma
por: Crain, Charles Nicolas, et al.
Publicado: (2021)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer
por: Nistor, Andreea, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_9uklqd90io1la9lp44kskrpor3